These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 22234312

  • 1. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
    Ofosu FA.
    Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
    [Abstract] [Full Text] [Related]

  • 2. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R, Bick RL.
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
    Harenberg J.
    Clin Appl Thromb Hemost; 2011 Dec; 17(6):E158-64. PubMed ID: 21406409
    [Abstract] [Full Text] [Related]

  • 5. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [Abstract] [Full Text] [Related]

  • 6. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J, Walenga JM, Jeske WP, Hoppensteadt DA, Fareed J, Wahi R, Bick RL.
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C, Jeske WP, Hoppensteadt D, Walenga JM, Bansal V, Fareed J.
    Clin Appl Thromb Hemost; 2009 Jul; 15(2):137-44. PubMed ID: 19357102
    [Abstract] [Full Text] [Related]

  • 9. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM, Jackson CM, Kessler CM.
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [Abstract] [Full Text] [Related]

  • 10. Recommendations on biosimilar low-molecular-weight heparins.
    Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J, Mismetti P, Ofosu FA, Raake W, Samama M, Schulman S, Subcommittee on Control of Anticoagulation of the SSC of the ISTH.
    J Thromb Haemost; 2009 Jul; 7(7):1222-5. PubMed ID: 19323788
    [Abstract] [Full Text] [Related]

  • 11. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S, Huys I.
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [Abstract] [Full Text] [Related]

  • 12. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I, Kaspar B, Sharma U.
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [Abstract] [Full Text] [Related]

  • 13. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J, Haas S, Sasahar A.
    Semin Thromb Hemost; 1999 Feb; 25 Suppl 3():145-7. PubMed ID: 10549730
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. SASAT (South Asian Society on Atherosclerosis & Thrombosis) proposal for regulatory guidelines for generic low-molecular weight heparins (LMWHs).
    Kalodiki E, Leong W, SASAT and Task Force on Generic LMWHs.
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):8-11. PubMed ID: 19117962
    [No Abstract] [Full Text] [Related]

  • 18. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.
    Cohen M, Jeske WP, Nicolau JC, Montalescot G, Fareed J.
    J Thromb Thrombolysis; 2012 Apr; 33(3):230-8. PubMed ID: 22234748
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.